| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00105-005-0927-4 |
| P698 | PubMed publication ID | 15887051 |
| P2093 | author name string | H Breuninger | |
| M Möhrle | |||
| P2860 | cites work | A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia | Q70535936 |
| Malignant melanoma patients with positive nodes and relatively good prognoses: Microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes | Q70755933 | ||
| Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger | Q71545789 | ||
| Lymph node metastases of cutaneous melanoma: diagnosis by B-scan and color Doppler sonography | Q73115233 | ||
| Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial | Q73668810 | ||
| Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma: results of a prospective study of 1288 patients | Q73911290 | ||
| A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma | Q73969439 | ||
| Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma | Q74081681 | ||
| Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status | Q74588262 | ||
| The Augsburg experience: histological aspects and patient outcomes | Q74618065 | ||
| Outcome of patients with melanoma and histologically negative sentinel lymph nodes | Q77310599 | ||
| Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy | Q77448215 | ||
| The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma | Q80488191 | ||
| The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies | Q33985999 | ||
| Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma | Q34086791 | ||
| Gamma-probe-guided lymph node localization in malignant melanoma | Q34349420 | ||
| An approach for the treatment of penile carcinoma | Q34354540 | ||
| Sentinel Lymph Node Biopsy Has No Benefit for Patients with Primary Cutaneous Melanoma Metastatic to a Lymph Node: An Assertion Based on Comprehensive, Critical Analysis | Q35539177 | ||
| Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma | Q35545019 | ||
| Management of cutaneous melanoma | Q35877006 | ||
| Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience | Q40757470 | ||
| Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. | Q40772239 | ||
| Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients | Q40821958 | ||
| Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients | Q44190417 | ||
| Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease | Q47258418 | ||
| Prognostic value of size of lymph node metastases in patients with cutaneous melanoma | Q47348250 | ||
| Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful? | Q47733143 | ||
| The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. | Q50504937 | ||
| How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma? | Q50510377 | ||
| Cervical sentinel lymph node biopsy for melanomas of the head and neck and upper thorax. | Q50513460 | ||
| Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. | Q50752731 | ||
| Slow infusion tumescent anesthesia. | Q51506729 | ||
| Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. | Q53355519 | ||
| Micrometastasis of a sentinel lymph node in cutaneous melanoma is a significant prognostic factor for disease-free survival, distant-metastasis-free survival, and overall survival. | Q54699271 | ||
| Technical details of intraoperative lymphatic mapping for early stage melanoma | Q68089035 | ||
| Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study | Q69597256 | ||
| Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities | Q70332864 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 441-447 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Die Dermatologie | Q15756740 |
| P1476 | title | [Sentinel node biopsy. What are the facts?] | |
| P478 | volume | 56 |
| Q43501351 | Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma >or=1 mm. | cites work | P2860 |
Search more.